Aerobic Capacity Enhancement
How mitochondrial peptides may improve aerobic performance markers.
Aerobic Capacity Determinants
A classic review (Bassett and Howley, 2000) found VO2max is limited mainly by oxygen delivery. Muscle mitochondria matter more for lactate threshold.
VO2max Components
| Factor | Peptide Target |
|---|---|
| Cardiac output | Indirect |
| Oxygen delivery | Indirect |
| Mitochondrial density | Proposed target |
Mitochondrial Peptide Effects
MOTS-c for Endurance
| Effect | Mechanism | Evidence |
|---|---|---|
| AMPK activation | Metabolic switch | Rodent studies |
| Fat oxidation | Fuel efficiency | Rodent studies |
| Insulin sensitivity | Fuel management | Rodent studies |
In a 2021 study, MOTS-c improved physical performance in mice of all ages. As of October 2026, no published study has given MOTS-c to people. See our MOTS-c profile.
SS-31 for Endurance
| Effect | Mechanism | Evidence |
|---|---|---|
| ATP efficiency | Less oxygen waste | Aged mice |
| Reduced ROS | Less fatigue | Aged mice |
In aged mice, SS-31 extended treadmill endurance without adding mitochondria. The MMPOWER-3 trial (218 adults with mitochondrial myopathy) missed its primary endpoints, walking distance and fatigue. As of October 2026, elamipretide is a prescription medicine, Forzinity (FDA accelerated approval, September 19, 2025), only for Barth syndrome. More in our SS-31 profile.
Aerobic Performance Markers
Measured Effects
| Marker | Peptide Effect |
|---|---|
| VO2max | Not measured in humans |
| Lactate threshold | Unknown |
| Running economy | Unknown |
| Time to exhaustion | Longer in mice |
Practical Applications
No study has tested either peptide in healthy athletes. Forum users report mixed results with MOTS-c. WADA's 2026 Prohibited List names MOTS-c under S4.4.1, prohibited at all times; as of October 2026, SS-31's status is unverified.
Training Integration
No study supports matching peptides to training phases. See the endurance applications overview.
Current Limitations
| Factor | Reality |
|---|---|
| Human research | None in athletes |
| Optimal protocols | Unknown |
| Performance data | Primarily animal |
| Availability | MOTS-c unapproved; elamipretide prescription-only |
Synergistic Approaches
| Combination | Rationale | Tested with peptides? |
|---|---|---|
| Altitude training | Mitochondrial stimulus | No |
| Heat acclimation | Additional stress | No |
| Periodized nutrition | Metabolic flexibility | No |
What We Still Don't Know
Mitochondrial peptides show theoretical promise for endurance but lack human validation. Whether either changes VO2max or lactate threshold is untested.
Stay Updated on Peptide Research
Get weekly breakdowns of new studies, dosing insights, and community protocols. No spam, unsubscribe anytime.
References
- Limiting factors for maximum oxygen uptake and determinants of endurance performance (Medicine & Science in Sports & Exercise, 2000)
- MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis (Nature Communications, 2021)
- SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice (Free Radical Biology and Medicine, 2019)
- Elamipretide in primary mitochondrial myopathy: the MMPOWER-3 randomized clinical trial (Neurology, 2023)
- FDA grants accelerated approval to first treatment for Barth syndrome (FDA, September 2025)
- 2026 Prohibited List (WADA, 2025)